
Opinion|Videos|September 3, 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Medical experts offer insights on the COMMANDS trial findings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Most Favored Nation Drug Pricing Moves Forward, but Experts Warn Details Are Still Missing
2
Trump Announces Deals With Eli Lilly, Novo Nordisk for Lower Weight Loss Drug Prices
3
Explore the Clinical Data for JOURNAVX® (suzetrigine)
4
FDA Approves Lumateperone as Add-On Therapy for Major Depressive Disorder
5











































